MedTrace Logo

Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.

NCT05369104 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-06-22

No results posted yet for this study

Summary

Pilot non comparative study assessing the clinical control of infection of DAIR + SAT +NaCl and DAIR + SAT + Phages anti-Staphylococcus aureus in patients with Staphylococcus aureus Prosthetic Joint Infection with an indication of DAIR + SAT.

Conditions

  • Infection of Total Hip Joint Prosthesis
  • Infection of Total Knee Joint Prosthesis

Interventions

BIOLOGICAL

Anti-Staphylococcus aureus Bacteriophages

Single intra-articular injection

Sponsors & Collaborators

  • Phaxiam Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-12-16
Completion
2025-06-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369104 on ClinicalTrials.gov